Dent Neurologic

Research Study

Menstrual Migraine Prevention

Menstrual Migraine Prevention using Ubrelvy This study will evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension Inclusion Criteria: In order to be eligible for this study, you must be at least 18 years old and have a diagnosis of Menstrual Migraine What to Expect […]

Menstrual Migraine Prevention Read More »

SANOFI Freviva

Sanofi Freviva The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis. Inclusion Criteria: 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years, without clinical

SANOFI Freviva Read More »

PIPELINE/CONTINEUM VISTA

PIPELINE/CONTINEUM VISTA This is a randomized, double-blind study of PIPE-307 or placebo to see if it can help patients with relapsing-remitting multiple sclerosis. Inclusion Criteria: 18-50 years of age, a diagnosis of relapsing-remitting multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years Without clinical MS relapse or treatment with corticosteroids within last 6

PIPELINE/CONTINEUM VISTA Read More »

IGC Pharma CALMA

IGC Pharma CALMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What

IGC Pharma CALMA Read More »

SUVEN CTP3S1502HT6

SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria:  50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study

SUVEN CTP3S1502HT6 Read More »

ADCS BENFO-TEAM

ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria:  50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study

ADCS BENFO-TEAM Read More »

OXA1 Study

0XA1 Study This study will test if an investigational medicine (a Medicine being studied) could safely reduce weight in people with obesity or overweight. Inclusion Criteria: Aged 18 to 75 years old  Do NOT have diabetes  have obesity (BMI of 30 or more) or have overweight (BMI of 27 or more) and a health condition:

OXA1 Study Read More »

Generation HD-2

Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study:   25 Years to 50 Years   (Adult) Sexes Eligible for Study:   All Generation HD-2 Link

Generation HD-2 Read More »

Scroll to Top